Vertex Pharmaceuticals OCI available-for-sale securities adjustment decreased by 52.7% to $3.50M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 94.8%, from $66.70M to $3.50M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates rising market values for the company's debt portfolio, while a decrease suggests market-driven depreciation of these assets.
This metric represents the net change in the fair value of debt securities classified as available-for-sale, recognized...
Common in financial institutions and large-cap firms with significant treasury investment portfolios.
is_jpm_oci_available_for_sale_securities| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $2.43M | $2.43M | $2.43M | $2.43M | -$5.40M | $66.70M | $7.40M | $3.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -322.7% | >999% | -88.9% | -52.7% |
| YoY Change | — | — | — | — | -322.7% | >999% | +237.0% | -94.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.